FindTrial
Sign In

Changes in Myocardial Perfusion During Chronic Multi Site Biventricular Versus Right Ventricular Apex Pacing in Patients With Normal Left Ventricular Function Undergoing His Bundle Ablation for Drug-refractory Atrial Fibrillation

Changes in Myocardial Perfusion During Chronic Multi Site Biventricular Versus Right Ventricular Apex Pacing in Patients With Normal Left Ventricular Function Undergoing His Bundle Ablation for Drug-refractory Atrial Fibrillation

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00528307
Acronym
SOS
Enrollment
5
Registered
2007-09-12
Start date
2007-10-31
Completion date
2010-12-31
Last updated
2014-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

myocardial perfusion, His ablation, biventricular pacing, His bundle ablation for atrial fibrillation

Brief summary

To determine whether Biventricular pacing in patients undergoing HIS bundle ablation for atrial fibrilation has beneficial effects on myocardial perfusion and left ventricularr ejection fraction.

Interventions

DEVICEHIS buldle ablation

HIS bundle ablation, followed by implant of a biventricular pacemaker

Sponsors

R&D Cardiologie
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Normal to nearly normal LVF (EF \> 40%) * Drug-refractory, persistent or permanent atrial fibrillation * Referred for His ablation

Exclusion criteria

* Unwilling or unable to sign the informed consent * Life expectancy \< 1year from non-cardiac causes * Previous myocardial infarction * Previous coronary bypass surgery * Poor left ventricle function (EF\< 40%) from any cause * Symptomatic obstructive coronary artery disease * Poor ultra sound imaging quality.

Design outcomes

Primary

MeasureTime frame
Difference in size of myocardial perfusion abnormalities in the two treatment groups as measured with MPS.6 months

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026